The biotechnology company focuses on researching rare neurodevelopmental, psychiatric, and neurodegenerative disorders through patient-centric translational research that integrates clinical and preclinical studies. This approach enhances the understanding and treatment options for these complex conditions, addressing the significant gap in knowledge and therapeutic development.
Funding
$540K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Drug discovery and treatment development for rare neurodevelopmental, psychiatric, and neurodegenerative disorders are hindered by a lack of translational research models and validated biomarkers. Understanding the underlying biology of these complex conditions and identifying effective therapeutic interventions requires bridging the gap between preclinical and clinical studies.
Solution
Ulysses Neuroscience is a biotechnology company providing preclinical and clinical research services to pharmaceutical companies, accelerating drug discovery programs for brain disorders. The company employs translational neuroscience to connect preclinical and clinical research, focusing on patient-centric approaches. Ulysses Neuroscience integrates clinical insights with preclinical research platforms, including in-vivo electrophysiological and behavioral research, biomarker analysis, and iPSC-derived organoid models, to identify novel drug targets and develop effective therapies. The company specializes in identifying translational peripheral molecular and neurophysiological biomarkers of disease progression, with a particular focus on synaptic plasticity and microtubule dynamics.
Target Audience
The primary customers are pharmaceutical companies engaged in drug discovery and development for neuropsychiatric, neurodegenerative, and rare neurological disorders.
Features
- Clinical research services, including patient community engagement and biomarker identification
- In-vivo research capabilities, including disease models for neurodevelopmental, neuropsychiatric, and neurodegenerative disorders
- Behavioral analysis, including cognitive, stress/anxiety, sociability, and motor system assessments
- Electrophysiology platform for EEG recordings in rats, focusing on home cage and operant chamber-based recordings
- Capabilities for amperometry and voltammetry to measure real-time changes in neurochemistry in freely-moving animals
- In-vitro research capabilities, including primary culture systems and iPSC/organoid platforms
- Cellular/molecular methodologies, including infrared Western blot, multiplex MESO Scale Discovery, immunohistochemistry, real-time PCR, ELISA, and HPLC
- Expertise in synaptic pathology, neuroinflammation, and cytoskeleton integrity
- Licensed for the use of Schedule I drugs (glutamatergic and serotonergic psychedelics) for research